inclusion criteria: * adults males or females between 18-60 years of age at the day of screening. * willing and able to comply with scheduled visits, laboratory test, complete diaries and other study procedures. * body mass index 18 to 40 kg/m2 at screening. * covid19 negative quick test or pcr test and negative serum igg binding antibody response to the sars-cov-2 s glycoprotein at screening or prior the first vaccination. if an enrolled subject has neutralizing antibodies at baseline, he or she will be excluded from final analysis. * willing to avoid all other vaccines within 4 weeks before and after each injection. seasonal influenza vaccination is allowed if it is received at least 14 days before or after the vaccination. * women of childbearing potential must have a negative pregnancy test in urine before the inclusion of the study and prior to each vaccination. * if female of childbearing potential, willing to use highly effective contraceptive methods or have practiced sexual abstinence from the screening visit until 8 weeks after the last injection. * if male and not sterilized, willing to avoid impregnating female partners from screening until 8 weeks after last injection. * willing and able to provide written informed consent prior the initiation of any study procedures.

inclusion criteria: * adults males or females between 18-60 years of age at the day of screening. * willing and able to comply with scheduled visits, laboratory test, complete diaries and other study procedures. * body mass index 18 to 40 kg/m2 at screening. * covid19 negative quick test or pcr test and negative serum igg binding antibody response to the sars-cov-2 s glycoprotein at screening or prior the first vaccination. if an enrolled subject has neutralizing antibodies at baseline, he or she will be excluded from final analysis. * willing to avoid all other vaccines within 4 weeks before and after each injection. seasonal influenza vaccination is allowed if it is received at least 14 days before or after the vaccination. * women of childbearing potential must have a negative pregnancy test in urine before the inclusion of the study and prior to each vaccination. * if female of childbearing potential, willing to use highly effective contraceptive methods or have practiced sexual abstinence from the screening visit until 8 weeks after the last injection. * if male and not sterilized, willing to avoid impregnating female partners from screening until 8 weeks after last injection. * willing and able to provide written informed consent prior the initiation of any study procedures.

inclusion criteria: adults males or females between 18-60 years of age at the day of screening. willing and able to comply with scheduled visits, laboratory test, complete diaries and other study procedures. body mass index 18 to 40 kg/m2 at screening. covid19 negative quick test or pcr test and negative serum igg binding antibody response to the sars-cov-2 s glycoprotein at screening or prior the first vaccination. if an enrolled subject has neutralizing antibodies at baseline, he or she will be excluded from final analysis. willing to avoid all other vaccines within 4 weeks before and after each injection. seasonal influenza vaccination is allowed if it is received at least 14 days before or after the vaccination. women of childbearing potential must have a negative pregnancy test in urine before the inclusion of the study and prior to each vaccination. if female of childbearing potential, willing to use highly effective contraceptive methods or have practiced sexual abstinence from the screening visit until 8 weeks after the last injection. if male and not sterilized, willing to avoid impregnating female partners from screening until 8 weeks after last injection. willing and able to provide written informed consent prior the initiation of any study procedures.

inclusion criteria: adults males or females between 18-60 years of age at the day of screening. willing and able to comply with scheduled visits, laboratory test, complete diaries and other study procedures. body mass index 18 to 40 kg/m2 at screening. covid19 negative quick test or pcr test and negative serum igg binding antibody response to the sars-cov-2 s glycoprotein at screening or prior the first vaccination. if an enrolled subject has neutralizing antibodies at baseline, he or she will be excluded from final analysis. willing to avoid all other vaccines within 4 weeks before and after each injection. seasonal influenza vaccination is allowed if it is received at least 14 days before or after the vaccination. women of childbearing potential must have a negative pregnancy test in urine before the inclusion of the study and prior to each vaccination. if female of childbearing potential, willing to use highly effective contraceptive methods or have practiced sexual abstinence from the screening visit until 8 weeks after the last injection. if male and not sterilized, willing to avoid impregnating female partners from screening until 8 weeks after last injection. willing and able to provide written informed consent prior the initiation of any study procedures.